Improvement of idiopathic pyoderma gangrenosum during treatment with anti-tumor necrosis factor alfa monoclonal antibody

International Journal of Lower Extremity Wounds

Volumn 6, Issue 2, 2007, Pages 108-113

  Dini, Valentina ^a   Romanelli, Marco ^a   Bertone, MariaStefania ^a   Talarico, Sara ^a   Bombardieri, Stefano ^a   Barachini, Paolo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Anti TNF alfa; Infliximab ; Leg ulcers; Pyoderma gangrenosum

Indexed keywords

ANTIBIOTIC AGENT; CYCLOSPORIN; INFLIXIMAB; METHYLPREDNISOLONE;

ADULT; AGED; ANAMNESIS; ARTICLE; BACTERIUM CULTURE; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; COLOR ULTRASOUND FLOWMETRY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOOT ULCER; HUMAN; HUMAN TISSUE; LABORATORY TEST; LEG INJURY; LEG ULCER; PRIORITY JOURNAL; PUNCH BIOPSY; PYODERMA GANGRENOSUM; THORAX RADIOGRAPHY; UNSPECIFIED SIDE EFFECT; WOUND CARE;

AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIPHOSPHOLIPID SYNDROME; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LEG ULCER; MIDDLE AGED; PYODERMA GANGRENOSUM; TUMOR NECROSIS FACTOR-ALPHA; WOUND HEALING;

EID: 34250186090     PISSN: 15347346     EISSN: 15526941     Source Type: Journal    
DOI: 10.1177/1534734607300912     Document Type: Article

References (20)

1. Chakrabarty A., Phillips T. Leg ulcers of unusual causes. Int J Lower Extremity Wounds 2003 ; 2 (4). 207-16.
2. Choucair MM, Fivenson DP Pyoderma gangrenosum: a review of the disease and treatment options. Wounds 2001 ; 13 (3). 119-22.
3. Burns T., Breathnach S., Cox N., Griffiths C. Pyoderma gangrenosum. In: Blackwell Science, editor. Rook's text book of dermatology. Oxford (UK): Blackwell Science ; 2005. p. 49.36-49. 39.
4. Reichrath J., Bens G., Bonowitz A., Tilgen W. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 2005 ; 53 (2). 273-83.
5. Livideanu C., Lpsker D., Paul C., Juillard J., Schubert B. Pyoderma gangrenosum as initial manifestation of Graves'disease. Clin Exp Dermatol 2006 ; 31 (5). 659-61.
6. Provost TT Pyoderma gangrenosum. Adv Stud Med 2003 ; 3: 116-18.
7. Wolff K., Stingl G. Pyoderma gangrenosum. In: Freedberg IM, Eisen AZ, Wolff K, Austen FK, editors. Fitzpatrick's dermatology in general medicine. 5 th ed. New York: McGraw-Hill ; 1999. p. 1140-6.
8. Powell FC, Su WP, Perry HQ Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 1996 ; 34: 395-409.
9. Jorizzo JL, Solomon AR, Zanolli MD, Leshin B. Neutrophilic vascular reactions. J Am Acad Dermatol 1988 ; 19: 983-1005.
10. Hurwittz RM, Haseman JH The evolution of pyoderma gangrenosum: a clinicopathologic correlation. Am J Dermapathol 1993 ; 15: 28-33.
11. Powell FC, Schroeter AL, Su WP, Perry HO Pyoderma gangrenosum: a review of 86 patients. Q J Med 1985 ; 55: 173-86.
12. Rustin MH, Gilkes JJ, Robinson TW Pyoderma gangrenosum associated with Behcet's disease: treatment with thalidomide. J Am Acad Dermatol 1990 ; 23: 941-4.
13. Green SM, Kerdel FA, Falabella AF, Kirsner R. Infliximab: a treatment option for ulcerative pyoderma gangrenosum. Wounds 2003 ; 15 (2). 49-53.
14. McGowan JW 4th, Johnson CA, Lynn A. Treatment of pyoderma gangrenosum with etanercept. J Drugs Dermatol 2004 ; 3 (4). 441-4.
15. Hubbard VG, Friedmann AC, Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol 2005 ; 152: 1059-61.
16. Mouser JF, Hyams JS Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease. Clin Ther 1999 ; 21: 932-42.
17. Old LJ Tumor necrosis factor (TNF). Sci Am 1988 ; 258: 59-60, 69-75.
18. Van Deventer SJH. Tumor necrosis factor and Crohn's disease. Gut 1997 ; 40: 443-8.
19. Mouser JF, Hyams JS Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease. Clin Ther 1999 ; 21: 932-42.
20. Kaur MR, Lewis HM Severe recalcitrant pyoderma gangrenosum treated with infliximab. Br J Dermatol 2005 ; 153: 689-91.